Head-To-Head Review: Revvity (RVTY) and Its Competitors

Revvity (NYSE:RVTY) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its competitors? We will compare Revvity to related businesses based on the strength of its valuation, risk, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Dividends

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Revvity pays out 13.3% of its earnings in the form of a dividend. As a group, “Life Sciences Tools & Services” companies pay a dividend yield of 8.2% and pay out 44.5% of their earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of recent ratings for Revvity and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0	13	6	0	2.32
Revvity Competitors	948	3167	5484	177	2.50

Revvity currently has a consensus target price of $133.86, indicating a potential downside of 16.17%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 3.48%. Given Revvity’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Revvity has less favorable growth aspects than its competitors.

Profitability

This table compares Revvity and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revvity	8.61%	8.64%	5.24%
Revvity Competitors	-540.60%	-166.50%	-13.58%

Insider & Institutional Ownership

86.7% of Revvity shares are owned by institutional investors. Comparatively, 53.7% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Revvity and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Revvity	$2.86 billion	$241.20 million	76.04
Revvity Competitors	$2.27 billion	$55.88 billion	-14.04

Revvity has higher revenue, but lower earnings than its competitors. Revvity is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Revvity has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Revvity’s competitors have a beta of 0.94, meaning that their average stock price is 6% less volatile than the S&P 500.

Summary

Revvity beats its competitors on 8 of the 15 factors compared.

Revvity Company Profile

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.